Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 3Fallopian Tube Neoplasms 3Uterine Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma 2Hematologic Neoplasms 2Carcinoma, Renal Cell 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Muscle Invasive Bladder Cancer 1Meningeal Carcinomatosis 1Melanoma 1Lung Neoplasms 1Glioma 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Carcinoma 1Brenner Tumor 1

Interventions

Taxes 2Paclitaxel 2Immunoglobulin G 2Gemcitabine 2Disulfides 2Carboplatin 2Bevacizumab 2adavosertib 1X-Rays 1Specimen Handling 1Mesenchymal Stem Cell Transplantation 1Magnetic Resonance Spectroscopy 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Brenner Tumor × adavosertib × Clear all
NCT02101775 2026-04-13

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
124 enrolled 17 charts
Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡